Option chain shows key data for Dexus's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Dexus.

Dexus (OTC:DEXSF) Stock, Option Chain

Dexus has ownership interest in, manages, and develops a portfolio of office and industrial assets, about half located in Sydney. The office portfolio contributes nearly two-thirds of group earnings and industrial assets account for about 15%. Dexus also manages third-party assets and has a funds management platform with AUD 40 billion funds under management as of June 30, 2024, spanning office, industrial, retail, healthcare, infrastructure, and their adjacent sectors. The REIT has stakes in many of the pooled funds, earning distribution income. Management is internalized, in contrast to some of its peers.

Dexus

President-elect Donald Trump has chosen former Representative Doug Collins (R-GA) to lead the <a href="https://www.benzinga.com/cannabis">U.S. Department of Veterans Affairs (VA). </a>
The decision has sparked discussions about how the agency might handle medical cannabis issues, given his inconsistent track record on the issue, as <a href="https://www.marijuanamoment.net/trumps-pick-to-lead-va-voted-against-letting-agency-doctors-recommend-medical-marijuana-to-veterans-before-he-adopted-a-pro-reform-position/">reported</a> Marijuana Moment.
<h3 class="wp-block-heading">Collins' Record On Cannabis</h3>
During his time in Congress, Collins opposed efforts to expand access to medical cannabis for veterans. Between 2014 and 2016, he voted against three proposals that would have allowed VA doctors to recommend cannabis to their patients.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/42018478/trumps-cabinet-choices-will-his-administration-support-or-restrict-cannabis">Trump&#8217;s Cabinet Choices: Will His Administration Support Or Restrict Cannabis?</a>
Collins' views began to shift in 2019. He supported the STATES Act, which would protect state marijuana programs from federal interference, and co-signed a letter with Rep. Matt Gaetz (R-FL), urging Congress to take action on cannabis policy. 
"We believe this Committee and this Congress must act to clarify the rights and responsibilities, relative to cannabis, of individuals, physicians, businesses, medical patients, and law enforcement officials," they wrote.
Later that year, Collins backed a bipartisan bill to protect banks that serve marijuana businesses in states where it is legal. However, he did not take part in a 2020 vote on federal cannabis legalization.
<h3 class="wp-block-heading">Collins' Stance On Psychedelics</h3>
When it comes to psychedelics, there isn't much known about Collins's stance. However, his shifting views on cannabis policy hint that he could be open to exploring different approaches.
<h3 class="wp-block-heading">Cannabis At The VA</h3>
VA policy has long prohibited its doctors from recommending cannabis, citing marijuana's classification as a Schedule I controlled substance under federal law. This stance has remained consistent across both Republican and Democratic administrations, despite growing support for change in Congress.
Recent efforts to address this issue include a Senate Appropriations Committee request for the VA to explore cannabis as an alternative to opioids. Lawmakers have also introduced measures that would allow VA doctors to recommend cannabis in states where it is legal. These efforts have gained bipartisan support, but none have yet become law.
Veterans service organizations have pushed for further reforms, including expanded research into the potential benefits of cannabis. Last year, a Senate committee approved a bill to study cannabis for veterans with certain medical conditions, but it failed to advance to a floor vote.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42017583/trumps-go-wild-on-health-plan-puts-rfk-jr-in-charge-what-it-means-for-cannabis-and-psychedelics-reform">Trump&#8217;s &#8216;Go Wild On Health&#8217; Plan Puts RFK Jr. In Charge: What It Means For Cannabis And Psychedelics Reform</a></li>
</ul>
Cover image made with AI.

Cannabis

Government

News

Psychedelics

Politics

Markets

Trump-Appointed Doug Collins To Lead VA: What's Next For Cannabis and Psychedelics In Veterans' Healthcare?

Chardan Capital analyst Daniil Gataulin maintains Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) with a Buy and maintains $6 price target.

Price Target

Analyst Ratings

CLSD

Chardan Capital Maintains Buy on Clearside Biomedical, Maintains $6 Price Target

Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) with a Buy and maintains $11 price target.

CGTX

Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target

Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and maintains $165 price target.

Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Maintains $165 Price Target

– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation –
– Syndax to host conference call today at 6:00 p.m. ET –
WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj&#xAE; (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older. The FDA previously granted Breakthrough Therapy and Fast Track designations as well as Priority Review for Revuforj. The New Drug Application (NDA) received approval through the FDA's Real Time Oncology Review (RTOR) program.

Biotech

General

SNDX

Syndax Announces FDA Approval Of Revuforj, The First And Only Menin Inhibitor To Treat Adult And Pediatric Patients With Relapsed Or Refractory Acute Leukemia With A KMT2A Translocation

IT Tech Packaging (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ITP#AMEX">ITP</a>) reported quarterly losses of $(0.20) per share. This is unchanged from the same period last year. The company reported $25.08 million in sales this quarter. This is a 59.03 percent increase over sales of $15.77 million the same period last year.

Earnings

IT Tech Packaging Q3 EPS $(0.20), Same YoY, Sales $25.08M Up From $15.77M YoY

RumbleOn, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>) (the "Company" or "RumbleOn") announced today that the close of business (4:00 p.m. Central Time) on November 25, 2024 has been fixed as the record date (the "Record Date") for its previously announced proposed $10.0 million registered equity rights offering (the "Rights Offering"), which was announced in a Form 8-K filed with the U.S. Securities and Exchange Commission ("SEC") on November 12, 2024.

Offerings

RMBL

RumbleOn Announces That The Close Of Business On November 25, 2024 Has Been Fixed As The Record Date For Its Previously Announced Proposed $10M Registered Equity Rights Offering

Telsey Advisory Group analyst Dana Telsey maintains European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) with a Outperform and maintains $8 price target.

EWCZ

Telsey Advisory Group Maintains Outperform on European Wax Center, Maintains $8 Price Target

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf" title="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf</a>

FOUR

Shift4 Payments Will Replace R1 RCM In The S&P Midcap 400 Effective Prior To The Opening Of Trading On Wednesday, November 20

China Green Agriculture, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CGA#NYSE">CGA</a>) has changed its name to Enlightify Inc., effective November 25, 2024. Its ticker symbol will change to ENFY effective November 25, 2024, and it is expected to begin trading under that symbol on November 26, 2024. The Company mainly produces and distributes humic acid-based compound fertilizers, other varieties of compound fertilizers and agricultural products through its subsidiaries in China.

China Green Agriculture Changes Name to Enlightify Inc.; Its Ticker Symbol Will Change To 'ENFY' Effective November 25, 2024, And It Is Expected To Begin Trading Under That Symbol On November 26, 2024

Alpha Cognition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) reported quarterly losses of $(0.31) per share. This is a 63.1 percent increase over losses of $(0.84) per share from the same period last year.

ACOG

Alpha Cognition Q2 EPS $(0.31) Up From $(0.84) YoY

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) with a Buy and maintains $31 price target.

NRXP

D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $31 Price Target

D. Boral Capital analyst Jason Kolbert maintains VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) with a Buy and maintains $5 price target.

VNRX

D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target

Luna Innovations Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNA#NASDAQ">LUNA</a>) (the "Company"), a global leader in advanced fiber optic-based technology, today announced that it has received a written notice (the "Notice") on November 14, 2024, from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the quarter ended September 30, 2024 (the "Q3 2024 Form 10-Q") and because the Company remains delinquent in filing its Form 10-Qs for the quarters ended March 31, 2024 (the "Q1 2024 Form 10-Q") and June 30, 2024 (the "Q2 2024 Form 10-Q") and its Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K", and collectively with the Q1 2024 10-Q, Q2 2024 10-Q and Q3 2024 10-Q, the "Delinquent Filings"), it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). As previously announced, the Company received earlier notices of non-compliance with respect to the Rule on August 20, 2024, May 17, 2024 and April 2, 2024 because it had not yet filed its Q2 2024 Form 10-Q, Q1 2024 Form 10-Q and 2023 Form 10-K, respectively.
This Notice has no immediate effect on the listing of the Company's shares on Nasdaq. However, if the Company fails to timely regain compliance with the Rule, the Company's common stock will be subject to delisting from Nasdaq.
As previously disclosed on October 7, 2024, the Company intended to appeal a determination by the Nasdaq Listing Qualifications Department to delist the Company's securities due to the Company's Delinquent Filings. On October 8, 2024, the Company timely requested a hearing before the Nasdaq Hearings Panel (the "Panel") and requested that the automatic stay of suspension be extended through the completion of the hearings process and the expiration of any additional extension period granted by the Panel following the hearing. The hearing is scheduled for November 26, 2024 and the request for the automatic stay of suspension was granted.
The Company is working diligently to complete its Delinquent Filings and will provide an update once more information is available.

LUNA

Luna Innovations Receives Additional Notice From Nasdaq Regarding Late Filing Of Quarterly Report On Form 10-Q; Hearing Is Scheduled For November 26, 2024 And The Request For The Automatic Stay Of Suspension Was Granted

Barrington Research analyst Kevin Steinke maintains HireQuest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQI#NASDAQ">HQI</a>) with a Outperform and raises the price target from $17 to $18.

Barrington Research Maintains Outperform on HireQuest, Raises Price Target to $18

Barrington Research analyst Vincent Colicchio maintains Alithya Group (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ALYA#TSX">ALYA</a>) with a Outperform and maintains C$3.5 price target.

TSX:ALYA

Barrington Research Maintains Outperform on Alithya Group, Maintains C$3.5 Price Target

Lifeway Foods, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWAY#NASDAQ">LWAY</a>) ("Lifeway" or the "Company"), a leading U.S. supplier of kefir and fermented probiotic products to support the microbiome, confirmed that it has received a revised, unsolicited, non-binding proposal from Danone North America PBC ("Danone") to acquire all outstanding shares of common stock of Lifeway it does not already own for $27.00 per share in cash. According to the Schedule 13D amendment filed today with the U.S. Securities and Exchange Commission disclosing the revised proposal, Danone beneficially owns approximately 23.3% of Lifeway's outstanding common stock.
On November 5, 2024, Lifeway announced that its Board of Directors (the "Board") had rejected Danone's initial unsolicited, non-binding proposal to acquire all the shares of Lifeway that it does not already own for $25.00 per share because the Board determined that the initial proposal substantially undervalued Lifeway and was not in the best interests of the Company and its shareholders and other stakeholders.
Consistent with its fiduciary duties, Lifeway's board of directors, in consultation with its independent outside advisors, will carefully review and evaluate the revised proposal to determine the course of action that it believes is in the best interests of the Company and its shareholders and other stakeholders.
The Company does not undertake any obligation to provide any updates with respect to this or any other proposal or transaction, except as required under applicable law.
Lifeway shareholders do not need to take any action at this time.
Evercore is serving as a financial advisor to Lifeway and Sidley Austin LLP is serving as legal counsel to Lifeway.

LWAY

Lifeway Foods Confirms Receipt Of Revised, Unsolicited, Non-Binding Proposal From Danone  To Acquire All Outstanding Shares Of Common Stock Of Lifeway It Does Not Already Own For $27.00 Per Share In Cash

Generation Income (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIPR#NASDAQ">GIPR</a>) reported quarterly losses of $(0.03) per share. This is unchanged from the same period last year. The company reported quarterly sales of $2.40 million which beat the analyst consensus estimate of $2.26 million by 6.21 percent. This is a 30.17 percent increase over sales of $1.84 million the same period last year.

Earnings Beats

GIPR

Generation Income Q3 FFO $(0.03), Same YoY, Sales $2.40M Beat $2.26M Estimate

Shareholders Approve Waiver Of 19.99% Limit To Enable Additional Stock Issuance

Stock Split

LUXH

LuxUrban Hotels Announces 1-For-70 Reverse Stock Split Effective Nov. 20 To Strengthen Nasdaq Compliance

COIN RISES OVER 9% AT THE HIGH OF THE DAY
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="646" height="677" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/15210221/Screen-Shot-2024-11-15-at-4.06.36-PM.png" alt="" class="wp-image-3372" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/15210221/Screen-Shot-2024-11-15-at-4.06.36-PM.png 646w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/15210221/Screen-Shot-2024-11-15-at-4.06.36-PM-286x300.png 286w" sizes="(max-width: 646px) 100vw, 646px" /></figure>
Today, Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:08 AM on November 15th, a significant trading signal occurred for Coinbase Global, Inc.as it demonstrated a Power Inflow at a price of $280.69. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Coinbase&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Coinbase&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for COIN, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data are brought to you by Benzinga APIs</a> and include firms, like <a href="https://finitusa.com/en/">Finit USA</a>, responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $280.69. The returns on the high price ($306.17) and close price ($305.82)&nbsp;after the power inflow were&nbsp;9.0% and 8.7%&nbsp;respectively. That is why it is important to have a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. In this case, the high of the day and close were very close but that is not always the case
Past Performance is Not Indicative of Future Results

Signals

Trading Ideas

COIN

Tradepulse Power Inflow Alert: Coinbase Global Inc. Receives Alert And Climbs Over 25 Points

Dexus (AU:DXS) has released an update. Dexus has announced its 2024 Annual General Meeting (AGM) for October 30, inviting shareholders to participa...

Dexus Schedules 2024 Hybrid Annual General Meeting

Jarden analyst Lou Pirenc maintained a Hold rating on Dexus (DEXSF – Research Report) today and set a price target of A$7.85. The company's shares ...

Jarden Keeps Their Hold Rating on Dexus (DEXSF)

Dexus (AU:DXS) has released an update. Dexus has announced the issuance of 1,299,457 fully paid stapled securities set to be issued on August 22, 2...

Dexus Announces Issuance of New Securities

Dexus (AU:DXS) has released an update. Dexus has announced a change in the interests of director Ross Du Vernet, disclosing the vesting and disposa...

Dexus Director's Stake Changes Amidst Role Shift

Dexus (AU:DXS) has released an update. Dexus has reported a resilient performance with strong occupancy rates in its property portfolio and robust ...

Dexus Demonstrates Resilience and Strategic Growth

Dexus (AU:DXS) has released an update. Dexus, a leading Australasian real asset group, held its 2024 Annual General Meeting, marking the first AGM ...

Dexus AGM Highlights Leadership Transition and Strategic Growth

Dexus (AU:DXS) has released an update. Dexus, a leading real asset group, announced the results of its 2024 Annual General Meeting, where key resol...

Dexus AGM: Key Approvals Amid Shareholder Dissent

In a report released today, Simon Chan from Morgan Stanley maintained a Sell rating on Dexus (DEXSF – Research Report), with a price target of A$8....

Dexus (DEXSF) Gets a Sell from Morgan Stanley

Morgan Stanley analyst Simon Chan maintained a Sell rating on Dexus (DEXSF – Research Report) today and set a price target of A$8.25. The company's...

Morgan Stanley Keeps Their Sell Rating on Dexus (DEXSF)

Dexus (AU:DXS) has released an update. Dexus has reported a change in the indirect interest of Director Rhoda Phillippo, who acquired an additional...

Comments

Dexus

Dexus (DEXSF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga